ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Deal Brings AstraZeneca Greater C
In VivoThe number of financings among life sciences companies in the TechBio sector increased from Q3 2023, stabilizing in H1 2024. During the period Q3 2023 – Q3 2024, a total of $6bn was raised, with the s
ScripBack in the bosom of BenevolentAI, the company he founded in 2013, Ken Mulvany has announced “a major strategic overhaul” and substantial cost-cutting program to return the UK-based artificial intelli
In VivoSince its founding in 1990, New York-based Schrödinger has functioned as a platform company, identifying, validating, optimizing clinical candidates and doing preclinical development for other compani